(Other OTC:TBTC),(OTC US:TBTC), MINNETONKA, Minn., Nov. 07, 2025 (GLOBE NEWSWIRE) — On November 7, 2025, The Board of Directors of Table Trac Inc. (the “Company”) (OTCQX: TBTC) approved a cash dividend on the Company's common stock of $0.02 per share. The dividend is payable on December 12, 2025, to shareholders of record at the close […]
Table Trac Announces Quarterly Dividend GlobeNewswire November 07, 2025 MINNETONKA, Minn., Nov. 07, 2025 (GLOBE NEWSWIRE) — On November 7, 2025, The Board of Directors of Table Trac Inc. (the “Company”) (OTCQX: TBTC) approved a cash dividend on the Company's common stock of $0.02 per share. The dividend is payable on December 12, 2025, to
NEW YORK, NY / ACCESS Newswire / November 7, 2025 / If you suffered a loss on your Fortinet, Inc. (NASDAQ:FTNT) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/fortinet-inc-lawsuit-submission-form?prid=176180&wire=1&utm_campaign=21 or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or call
(NASDAQ:ATYR), SAN FRANCISCO, Nov. 07, 2025 (GLOBE NEWSWIRE) — A new class action complaint has been filed against aTyr Pharma, Inc. (NASDAQ: ATYR) and certain of its top executives, significantly enlarging the alleged class period covered by the ongoing securities litigation. The firm urges investors in aTyr who suffered significant losses to submit your losses
aTyr Pharma, Inc. (ATYR) Failed Drug Trial Spurs Securities Lawsuit; Class Period Significantly Enlarged — Hagens Berman ATYR Investors with Losses Encouraged to Contact the Firm GlobeNewswire November 07, 2025 SAN FRANCISCO, Nov. 07, 2025 (GLOBE NEWSWIRE) — A new class action complaint has been filed against aTyr Pharma, Inc. (NASDAQ: ATYR) and certain of
(NASDAQ:MLTX), SAN FRANCISCO, Nov. 07, 2025 (GLOBE NEWSWIRE) — A securities class action, styled Bridgewood v. MoonLake Immunotherapeutics, et al., No. 1:25-cv-08500 (S.D.N.Y), has been filed after MoonLake (NASDAQ: MLTX) announced disastrous Phase 3 trial results for its only product candidate (sonelokimab, or “SLK”), its highly anticipated treatment for patients with skin disease (hidradenitis suppurativa
MLTX INVESTOR ALERT: MoonLake Immunotherapeutics (MLTX) Faces Securities Class Action After Company Reported Disastrous Phase 3 Trial Data For Sole Drug Candidate — Hagens Berman GlobeNewswire November 07, 2025 SAN FRANCISCO, Nov. 07, 2025 (GLOBE NEWSWIRE) — A securities class action, styled Bridgewood v. MoonLake Immunotherapeutics, et al., No. 1:25-cv-08500 (S.D.N.Y), has been filed after
New and active employer job postings for tech positions at highest volume in 12 months Employer job postings for information technology (IT) occupations are at their highest monthly volume in a year, according to analysis by CompTIA, the leading global provider of vendor-neutral IT training and certifications. https://mma.prnewswire.com/media/2608749/CompTIA_Logo_Logo.jpg There were 474,293 active employer job postings
The Ademi Firm is investigating Gulf Island (NASDAQ: GIFI) for possible breaches of fiduciary duty and other violations of law in its recently announced transaction with IES Holdings Inc. https://mma.prnewswire.com/media/2672539/Ademi_Fruchter__Logo.jpg Click here to learn how to join our investigation and obtain additional information or contact us at gademi@ademilaw.com or toll-free: 866-264-3995. There is no cost
LONDON, Nov. 07, 2025 (GLOBE NEWSWIRE) — Pixalate, the leading global platform for ad fraud protection, privacy, and compliance analytics, today released the United Kingdom (U.K.) October 2025 Publisher Trust Index (PTI) rankings for open programmatic advertising traffic quality across mobile apps on the Apple App Store, Google Play Store, websites, and major Connected TV